Go back to the enewsletter Seabourn has unveiled d

first_imgGo back to the enewsletterSeabourn has unveiled details of the submarines that will be offered aboard its expedition fleet from 2021. Seabourn Venture and her yet-to-be-named sister-ship will each carry a U-Boat Worx Cruise Sub 7 submersible, an underwater battery-powered craft that will take up to six guests to a depth of up to 300 metres below sea-level. They have been “designed specifically for Seabourn,” the cruise company said.But if the subs looks familiar, that’s because they are  the same vessel that Scenic Luxury Cruise & Tours will offer guests aboard Scenic Eclipse.Passengers on the Cruise Sub 7 are seated in two clear acrylic spheres that flank the centre pilot’s station, offering an awe-inspiring perspective of the marine world beneath the waves. The three passenger seats in each sphere are mounted on a rotating platform that can turn for best sightlines.To maximize the guest experience, Seabourn’s subs will be outfitted with a host of optional equipment to enhance this once-in-a-lifetime opportunity. A 4k underwater video camera system will record the world outside while an internal video recording system will capture imagery of guests inside as well as their direct surroundings. Video footage can then be downloaded and projected on large screens in the Discovery Center during lectures aboard the ships. A six-function manipulator arm capable of lifting up to 32 kg (about 70 pounds) will also be mounted on the side of the sub. In keeping with the luxury experience found on Seabourn, each sub on both ships will be outfitted with custom-embroidered leather upholstery, two air conditioning systems, a Bluetooth stereo system and champagne chiller for guests looking to toast their voyage of discovery.The subs will be operated multiple times per day in regions around the world where conditions are suitable. They will be equipped with underwater LED flood/spot lights, imaging sonar that acts as a second set of eyes and an advanced underwater tracking and navigation system.Seabourn Venture is scheduled to launch in June 2021, with a second yet-to-be-named sister ship slated to launch in May 2022.Lead rendering from the U-Boat Worx website of the Sub 7 – 1140 Go back to the enewsletterlast_img read more

Study lays foundation for treating drug alcohol addicts with noninvasive brain stimulation

Source:https://www.elsevier.com/about/press-releases/research-and-journals/magnetic-stimulation-dampens-brain-response-to-drug-cues-in-addiction May 15 2018In a study investigating the use of transcranial magnetic stimulation (TMS) for drug addiction, researchers at Medical University of South Carolina are the first to demonstrate that the noninvasive brain stimulation technique can dampen brain activity in response to drug cues in chronic alcohol users and chronic cocaine users. The findings are published in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.Although the last 50 years of clinical and preclinical research have demonstrated that addiction is a brain disease, there are still no neural circuit-based treatments for substance dependence or the brain functions involved in the disorder. “Here, for the first time, we demonstrate that a new non-invasive brain stimulation technique may be the first tool available to fill this critical void in addiction treatment development,” said senior author Colleen Hanlon, PhD.Elevated brain activity in response to drug cues–referred to as cue reactivity–occurs with many types of drugs, including nicotine, alcohol, marijuana, and cocaine. Cue reactivity also predicts relapse in addiction, so treatment approaches targeting the neural circuitry related to cue reactivity may directly impact cue-induced relapse in patients.”Therefore, these results have a tremendous potential to impact both basic discovery neuroscience as well as targeted clinical treatment development for substance dependence,” said Dr. Hanlon.First author of the paper Tonisha Kearney-Ramos, PhD, and colleagues performed two independent studies at the same time, one involving 25 people with cocaine use disorder and the other involving 24 people with alcohol use disorder. The participants received one session of TMS, which targeted magnetic stimulation to circuitry critical for drug-taking behaviors–the ventromedial prefrontal cortex. The real stimulation session was compared against a sham session that mimicked the experience of receiving TMS without actual brain stimulation.Related StoriesNeural pathways explain the relationship between imagination and willingness to helpStudy provides new insight into longitudinal decline in brain network integrity associated with agingResearchers measure EEG-based brain responses for non-speech and speech sounds in childrenBrain imaging before and after TMS revealed that when alcohol users viewed images of alcohol-related cues, such as a liquor bottle, the single TMS session significantly reduced their drug cue reactivity. The same was true for cocaine users when viewing images of cocaine-related cues.”Since cue reactivity has previously been associated with abstinence, these studies suggest a common mechanism for treatment effects across disorders, with fMRI serving as a promising neural readout of treatment effects,” said Cameron Carter, MD, Editor of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.However, it is still unclear if the changes in brain activity observed in the study will translate to reduced drug or alcohol use. The participants did not report any changes in their drug or alcohol craving after TMS. The authors think that repeated sessions of the targeted stimulation may be needed to see changes in self-reported craving. The researchers hope to answer this question in an ongoing clinical trial involving multiple TMS sessions in cocaine users.In addition to substance abuse, elevated cue-reactivity is a core symptom of many diseases, such as post-traumatic stress disorder, generalized anxiety disorder, traumatic brain injury, smoking, and obesity, said Dr. Hanlon. “Therefore, the treatment described in this manuscript may have implications far beyond the substance abuse field.” read more